Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Trial of the Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System in Patients With Coronary Artery Disease: BIOHEART-II

NCT03284255 is registered in ClinicalTrials.gov with Shanghai Bio-heart Biological Technology Co., Ltd. as lead sponsor.

NCT NCT03284255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03284255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Trial of the Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System in Patients With Coronary Artery Disease: BIOHEART-II
Lead sponsor
Shanghai Bio-heart Biological Technology Co., Ltd.
Phase
Not applicable
Overall status
Unknown status
Start date
September 11, 2017
Completion date
August 30, 2024
Enrollment
431 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

antineoplastic agents, coronary artery disease